Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
3.7
Journals
Metabolites
Special Issues
Psoriasis and Metabolic Syndrome
share announcement

Psoriasis and Metabolic Syndrome

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Lipid Metabolism".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 8425

Special Issue Editor

Prof. Anna Baran

E-Mail Website
Guest Editor
Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland
Interests: psoriasis; psoriatic arthritis; metabolic diseases; genetic and epigenetic factors; markers; therapy; immunology; pathogenesis; lipids
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is a chronic autoimmune and inflammatory disease affecting 2–4% of the population. To date, psoriasis has been regarded as a systemic disease closely related to numerous cardiometabolic disorders, especially metabolic syndrome (MS), which affects 20–60% of psoriatic. People with psoriasis have a shortened life expectancy, mainly due to cardiovascular diseases and increased relative risk of mortality in comparison to the general population, which correlates with the severity of the disease. The multidirectional relationship of psoriasis with various comorbidities is translated by common genetic or immunological inflammation, but especially with systemic metabolically driven inflammation, which is crucial in psoriasis pathogenesis and leads to the development of atherosclerosis, insulin resistance, and further cardiometabolic complications. There have been continuous research efforts searching for novel markers and metabolites to evaluate or screen for cardiometabolic risk in order to enable early detection, followed by more effective and newer therapeutic interventions.

This Special Issue, “Psoriasis and Metabolic Syndrome”, will present the current knowledge on psoriasis and its metabolic comorbidities, with a special emphasis on the newest contexts of the pathogenesis, treatment and validation of innovative potential markers to give readers a deeper understanding of these complex interrelations.

Prof. Anna Baran
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • metabolic diseases
  • genetic and epigenetic factors
  • markers
  • therapy
  • immunology
  • pathogenesis
  • lipids

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 4841 KB  
Article
Serum Semaphorin Alterations in Psoriasis: Links to Metabolic Status Rather than Disease Severity
by Anna Baran, Anna Stepaniuk, Justyna Magdalena Hermanowicz, Beata Sieklucka, Krystyna Pawlak, Dariusz Pawlak and Iwona Flisiak
Metabolites 2026, 16(3), 190; https://doi.org/10.3390/metabo16030190 - 12 Mar 2026
Viewed by 527
Abstract
Introduction: Psoriasis is an autoimmune systemic disease of not entirely understood pathogenesis. It remains a significant therapeutic challenge and, due to its various comorbidities, has a remarkable detrimental effect on patients’ wellbeing. Semaphorins (Sema) are a group of transmembrane, cell surface-attached and secretory [...] Read more.
Introduction: Psoriasis is an autoimmune systemic disease of not entirely understood pathogenesis. It remains a significant therapeutic challenge and, due to its various comorbidities, has a remarkable detrimental effect on patients’ wellbeing. Semaphorins (Sema) are a group of transmembrane, cell surface-attached and secretory proteins that might play an important role in psoriasis due to their presence on keratinocytes and the ability to stimulate the proinflammatory cytokine production. Aims: The study aimed to assess the concentration of Sema3A, Sema3E, Sema4A, Sema4D and Sema7A in serum samples of psoriatic patients and explore the correlation with disease activity and clinical and metabolic status. Materials and Methods: The study involved 60 patients with plaque psoriasis and 30 healthy volunteers matched for gender, age, and BMI. Results: The mean serum Sema3A, Sema3E and Sema4D levels were significantly higher in patients with psoriasis than controls (p < 0.01, p < 0.05 and p < 0.05, respectively). Contrarily, Sema4A and Sema7A were significantly lower (p < 0.001 and p < 0.05 respectively). Significant positive correlation between Sema3A and UREA was noted. Sema3A levels were significantly higher in moderately ill and overweight patients (p < 0.05, p < 0.01, respectively) and in patients with longer-lasting psoriasis and male patients compared to controls (both p < 0.05). Sema3E significantly negatively correlated with HDL and glucose levels. Sema4A was significantly lower in moderately and severe psoriatic patients (p < 0.0001, p < 0.01, respectively). Sema7A was significantly higher in moderately ill and overweight patients (p < 0.05, p < 0.01, respectively) and significantly lower in male patients and in those with longer lasting disease than in controls. None of the semaphorins correlated with psoriasis severity, total BMI, psoriasis duration and age. Conclusions: Psoriatic patients exhibited distinct alterations in circulating semaphorins, with significantly increased serum Sema3A, Sema3E and Sema4D, and reduced Sema4A and Sema7A compared with healthy subjects. Selected semaphorins demonstrated associations with metabolic parameters and patient characteristics, although none can serve as marker of disease severity. The findings indicate that semaphorins may reflect psoriasis-related systemic disturbances, but further studies are required to explore their potential with disease-associated metabolic or clinical profiles. Full article
(This article belongs to the Special Issue Psoriasis and Metabolic Syndrome)
►▼ Show Figures

Figure 1

12 pages, 757 KB  
Article
The Role of Visfatin/NAMPT in the Pathogenesis of Psoriasis
by Mateusz Matwiejuk, Agnieszka Kulczyńska-Przybik, Bartłomiej Łukaszuk, Hanna Myśliwiec, Piotr Myśliwiec, Adrian Chabowski, Barbara Mroczko and Iwona Flisiak
Metabolites 2025, 15(9), 590; https://doi.org/10.3390/metabo15090590 - 6 Sep 2025
Cited by 3 | Viewed by 1372
Abstract
Introdcution: Psoriasis is a complex, chronic, immunologically, inflammatory, and environmentally mediated disease which may affect not only the skin, but also nails, and joints. This dermatosis is known for hyperproliferation, parakeratosis, dysregulated differentiation of keratinocytes, lack of granular layer of the skin and [...] Read more.
Introdcution: Psoriasis is a complex, chronic, immunologically, inflammatory, and environmentally mediated disease which may affect not only the skin, but also nails, and joints. This dermatosis is known for hyperproliferation, parakeratosis, dysregulated differentiation of keratinocytes, lack of granular layer of the skin and impaired apoptosis of keratinocytes. Methods Fifty patients with psoriasis and twenty-eight healthy individuals were enrolled in the study. Serum samples were collected both from the psoriatic patients and patients with an inguinal hernia, who served as the control group. Visfatin levels were measured by enzyme-linked immunosorbent assay. Various proteins have been well described as key contributors to the complex pathogenesis of psoriasis. Results: In our study, we found that serum visfatin levels were significantly higher in the psoriatic group compared to the control group. Interestingly, we observed a positive and statistically significant correlation between serum visfatin levels and HDL-C concentrations in patients with psoriasis. Discussion: An elevated HDL-C level in psoriatic serum might be a sign of a compensatory response to systemic inflammation, or a marker of metabolic dysfunction, or an early prognostic signal in disease progression. However, no significant correlations were found between visfatin levels and the Psoriasis Area and Severity Index (PASI) score. Conclusions: In summary, our findings indicate that visfatin levels are significantly altered in the serum of patients with psoriasis compared to the control group and it could be a pivotal point of understanding the pathogenesis of psoriasis and a new way of implementing therapeutic procedures. Full article
(This article belongs to the Special Issue Psoriasis and Metabolic Syndrome)
►▼ Show Figures

Figure 1

14 pages, 2048 KB  
Article
Apolipoproteins in Psoriasis: The Effect of Acitretin Treatment and UVB Phototherapy
by Hanna Myśliwiec, Dorota Kozłowska, Katarzyna Hodun, Bartłomiej Łukaszuk, Agnieszka Owczarczyk-Saczonek, Adrian Chabowski and Iwona Flisiak
Metabolites 2025, 15(3), 196; https://doi.org/10.3390/metabo15030196 - 12 Mar 2025
Viewed by 1895
Abstract
Background: Psoriasis is a chronic, multi-system inflammatory disease frequently associated with metabolic syndrome and lipid disturbances. Apolipoproteins, as essential regulators of lipid metabolism, may play a critical role in these metabolic abnormalities, potentially influencing disease severity and systemic inflammation. The aim of this [...] Read more.
Background: Psoriasis is a chronic, multi-system inflammatory disease frequently associated with metabolic syndrome and lipid disturbances. Apolipoproteins, as essential regulators of lipid metabolism, may play a critical role in these metabolic abnormalities, potentially influencing disease severity and systemic inflammation. The aim of this study was to compare serum concentrations of chosen apolipoproteins in patients with psoriasis before and after treatment with acitretin or narrowband UVB (NB-UVB). Methods: This study was conducted on 39 patients with psoriasis. The concentration of nine apolipoproteins and C-reactive protein was quantified using the Bio-Plex Immunoassay Kit. Results: The serum concentrations of ApoA2, ApoC1, ApoD, ApoE, and ApoJ were higher in the acitretin group compared to the NB-UVB group before treatment, while the ApoA1/ApoA2 ratio was lower. We also observed a negative association between the Psoriasis Area and Severity Index (PASI) and ApoA1/ApoA2 ratio in the patients before the treatment. Conclusions: The results of this study confirm the presence of metabolic disturbances in psoriatic patients. The treatment with NB-UVB or acitretin did not cause any significant changes in the apolipoproteins profile. Thus, we found no detrimental impact of acitretin on the apolipoproteins profile, despite the observed rise in total cholesterol concentration after the treatment. Further research is needed to explore whether specific therapeutic approaches can modify these disturbances and potentially improve long-term cardiovascular outcomes in this population. Full article
(This article belongs to the Special Issue Psoriasis and Metabolic Syndrome)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 659 KB  
Review
Altered Lipid Metabolism in Psoriatic Arthritis: A Comprehensive Review
by Stanislava Popova-Belova, Mariela Geneva-Popova, Stefka Stoilova, Velichka Popova, Georgi Nikolov and Dimitar Nikolov
Metabolites 2026, 16(5), 287; https://doi.org/10.3390/metabo16050287 - 22 Apr 2026
Viewed by 417
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory disorder affecting both the joints and skin. Beyond musculoskeletal manifestations, patients with PsA frequently exhibit alterations in lipid metabolism, contributing to an increased risk of cardiovascular disease. Dyslipidemia in PsA arises from multiple mechanisms, including systemic [...] Read more.
Psoriatic arthritis (PsA) is a chronic inflammatory disorder affecting both the joints and skin. Beyond musculoskeletal manifestations, patients with PsA frequently exhibit alterations in lipid metabolism, contributing to an increased risk of cardiovascular disease. Dyslipidemia in PsA arises from multiple mechanisms, including systemic inflammation, insulin resistance, and imbalances in adipokines such as leptin, adiponectin, and resistin. A structured literature search was conducted in PubMed, Scopus, and Web of Science to identify relevant studies on lipid metabolism in psoriatic arthritis, and the evidence was synthesized narratively. PsA is also commonly associated with obesity and metabolic syndrome, further exacerbating dyslipidemia and cardiovascular risk. Interventions including weight loss, lifestyle modification, and anti-inflammatory treatments have been shown to improve lipid profiles and clinical outcomes. This review provides a comprehensive overview of current knowledge on altered lipid metabolism in PsA, highlighting underlying mechanisms, clinical implications, and therapeutic strategies to reduce cardiovascular risk. Full article
(This article belongs to the Special Issue Psoriasis and Metabolic Syndrome)
►▼ Show Figures

Figure 1

31 pages, 429 KB  
Review
Common Skin Diseases and Metabolic Syndrome: A Proinflammatory Chemokine Perspective
by Mateusz Matwiejuk, Hanna Myśliwiec, Agnieszka Mikłosz, Adrian Chabowski and Iwona Flisiak
Metabolites 2026, 16(4), 253; https://doi.org/10.3390/metabo16040253 - 10 Apr 2026
Viewed by 635
Abstract
Skin diseases frequently coexist with other disorders, such as metabolic syndrome, diabetes mellitus, depression, psoriatic arthritis, and cardiovascular disease. Altered levels of distinct chemokines, like CCL5/RANTES, CXCL12/SDF-1a, CCL7/MCP-3, CCL2/MCP-1, CXCL1/GROa, and the eotaxin family, contribute to the development and/or exacerbation of inflammation, which [...] Read more.
Skin diseases frequently coexist with other disorders, such as metabolic syndrome, diabetes mellitus, depression, psoriatic arthritis, and cardiovascular disease. Altered levels of distinct chemokines, like CCL5/RANTES, CXCL12/SDF-1a, CCL7/MCP-3, CCL2/MCP-1, CXCL1/GROa, and the eotaxin family, contribute to the development and/or exacerbation of inflammation, which is a common feature of numerous skin diseases as well as metabolic syndrome. The pathological and molecular connections between chronic inflammatory skin diseases and metabolic syndrome are increasingly recognized as being driven by shared inflammatory pathways, oxidative stress, and adipokine dysregulation. While systemic inflammation acts as a common thread, the precise mechanisms for some conditions remain partially understood. Nevertheless, the exact pathological and molecular connections between skin diseases (i.e., psoriasis, atopic dermatitis, pemphigus vulgaris, acute and chronic spontaneous urticaria, bullous pemphigoid, squamous cell carcinoma, alopecia areata, systemic sclerosis, discoid lupus erythematosus, diffuse large B-cell lymphoma) and metabolic syndrome are not yet fully understood. This narrative review summarizes the robust association between various chronic inflammatory skin diseases and metabolic syndrome in the context of pro-inflammatory chemokines. Full article
(This article belongs to the Special Issue Psoriasis and Metabolic Syndrome)
15 pages, 542 KB  
Review
The Association Between Psoriasis and Metabolic Syndrome in Children: A Narrative Review
by Mateusz Matwiejuk, Hanna Myśliwiec, Agnieszka Mikłosz, Adrian Chabowski and Iwona Flisiak
Metabolites 2025, 15(6), 377; https://doi.org/10.3390/metabo15060377 - 6 Jun 2025
Cited by 2 | Viewed by 2586
Abstract
Psoriasis is a common inflammatory skin disease with a complex pathogenesis consisting of genetic factors, immune dysfunction and environmental background. In adults, psoriasis is strongly associated with a higher risk of developing metabolic abnormalities; however, data in children are inconclusive. Metabolic syndrome (MetS) [...] Read more.
Psoriasis is a common inflammatory skin disease with a complex pathogenesis consisting of genetic factors, immune dysfunction and environmental background. In adults, psoriasis is strongly associated with a higher risk of developing metabolic abnormalities; however, data in children are inconclusive. Metabolic syndrome (MetS) is a group of conditions that include central and abdominal obesity, hypertension, dyslipidemia and hyperglycemia. Potential pathogenic mechanisms linking psoriasis with metabolic syndrome include releasing large amounts of proinflammatory cytokines such as interleukins (IL-17, IL-23) and tumor necrosis factor alpha (TNF-α). These abnormalities promote excessive keratinocyte proliferation and impaired differentiation, which leads to typical psoriatic skin lesions. This paper aims to assess the potential link between psoriasis and each component of metabolic syndrome in children. It is speculated that the same proinflammatory cytokines produced by Th17 cells are also implicated in the development and progression of various metabolic disorders in patients with a severe course of the disease. Psoriatic patients are at higher risk for development metabolic diseases such as diabetes mellitus and cardiovascular disease. Full article
(This article belongs to the Special Issue Psoriasis and Metabolic Syndrome)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop